Drug regulatory agencies role in the interaction between clopidogrel and proton pump inhibitors

American Journal of Gastroenterology

Volumn 106, Issue 7, 2011, Pages 1369-1370

  Saiz, Luis Carlos ^a   Lvarez, Jess ^a   Martínez, Henar ^a  

^a Serv Madrileño de Salud Inst de Invest Sanitaria del Hospital Universitario la Paz IdiPaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

DRUG EFFICACY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PHARMACODYNAMICS; PRIORITY JOURNAL;

DRUG INTERACTIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; TICLOPIDINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79960049216     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.126     Document Type: Letter

References (15)

1. Bhatt DL, Cryer BL, Contant CF, e t al., for the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
2. Abraham NS, Hlatky MA, Animan EM et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010; 105: 2533-49.
3. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). (26 January 2009). Free access on: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatients andProviders/DrugSafetyInformationfor HeathcareProfessionals/ucm079520.htm.
4. Food and Drug Administration. Information for Healthcare Professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). (17 November 2009). Free access on: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm190787.htm.
5. Food and Drug Administration. Plavix (clopidogrel bisulfate). US label (August 2010). Free access on: http://www.accessdata.fda.gov/drug satfda-docs/label/2010/020839s048lbl.pdf.
6. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. (29 May 2009). Free access on: http://www.conseil-scientifique. lu/fileadmin/files/Publications-externes/ PlavixPPI2009.pdf.
7. European Medicines Agency. Interaction between clopidogrel and proton-pump inhibitors. (17 March 2010). Free access on: http://www. ema.europa.eu/docs/en-GB/document-library/ Public-statement/2010/03/WC500076346. pdf.
8. MHRA. Clopidogrel and proton pump inhibitors: interaction-updated advice. D rug Safety Update 2010; 3: 4-5. Free access on: http://www.mhra. gov.uk/Safetyinformation/DrugSafetyUpdate/ CON087711.
9. Spanish Medicines Agency. Clopidogrel and proton pump inhibitors possible interaction. [Posible interacci ó n de clopidogrel con los inhibidores de la bomba de protones]. Informative Note 2009/07 (3 June 2009). Free access (in Spanish) on: http://www.aemps.es/ actividad/alertas/usoHumano/seguridad/NI- 2009-07-clopidogrel.htm.
10. Spanish Medicines Agency. Clopidogrel and proton pump inhibitors interaction: information updated and use recommendations. [Interacci ó n de clopidogrel con los inhibidores de la bomba de protones: actualizaci ó n de la informaci ó n y recomendaciones de uso]. Informative Note 2010/04 (26 April 2010). Free access (in Spanish) on: http://www.aemps.es/ actividad/alertas/usoHumano/seguridad/2010/ NI-2010-04-clopidogrel.htm.
11. Bhatt DL, Cryer B, Contant CF e t al. The COGENT trial: a prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, San Francisco, CA, USA, 24 September 2009.
12. O ' Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic Effect and clinical effi-cacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
13. Stanek EJ, Aubert R, Flockhart D e t al. A national study of the Effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco Outcomes Study. Presented at SCAI, Las Vegas 2009. Abstract O-11.
14. Wallentin L, Becker RC, Budaj AB, e t al., for the PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
15. Yasuda H, Yamada M, Sawada S e t al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy aft er coronary stenting. Intern Med 2009; 48: 1725-30.